Autotranslocation of the pigment epithelium-choroid complex in treatment of age-related macular degeneration scarring stage

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

The “gold standard” of the neovascular age-related macular degeneration treatment is the intravitreal administration of angiogenesis inhibitors. In subretinal macular fibrosis, antiangiogenic therapy is not effective. In such cases, subretinal surgery is used, in particular, autotranslocation of pigment epithelium-choroid complex. This paper presents a case of successful use of this method in a 77 y.o. female patient with subretinal fibrosis in the macular area as an outcome of neovascular age-related macular degeneration. An original method of translocation of “pedicled” pigment epithelium-choroid complex from the paramacular area to the macula was used. In 24 months, the visual acuity increased from 0.01 to 0.07; the central fixation was restored; the absolute positive central scotoma disappeared. During all the post-operative follow-up period, the full-rate pigment epithelium-choroid perfusion in the choroid of the translocated flap, the loss of choroidal neovascularization activity signs and of indications for intravitreal administration of angiogenesis inhibitors were proved.

作者简介

Sergei Sosnovskii

Federal State Autonomous Institution “S.N. Fedorov National Medical Research Center “MNTK “Eye Microsurgery” of the Ministry of Health of the Russian Federation

编辑信件的主要联系方式.
Email: svsosnovsky@mail.ru
ORCID iD: 0000-0002-1745-5146

Assistant-Professor, PhD, MD of Highest Qualification

俄罗斯联邦, Saint Petersburg

Ernest Boiko

Federal State Autonomous Institution “S.N. Fedorov National Medical Research Center “MNTK “Eye Microsurgery” of the Ministry of Health of the Russian Federation; North-Western State Medical University named after I.I. Mechnikov; S.M. Kirov Military Medical Academy

Email: boiko111@list.ru

Professor, Doctor of Medical Science, Honored MD of Russian Federation, Director; Professor, Head, Ophthalmology Department

俄罗斯联邦, Saint Petersburg

Dzhambulat Oskanov

Federal State Autonomous Institution “S.N. Fedorov National Medical Research Center “MNTK “Eye Microsurgery” of the Ministry of Health of the Russian Federation

Email: oskanovd@mail.ru

Ophthalmologist

俄罗斯联邦, Saint Petersburg

参考

  1. Либман Е.С., Калеева Э.В., Рязанов Д.П. Комплексная характеристика инвалидности вследствие офтальмопатологии в Российской Федерации // Российская офтальмология онлайн. – 2012. – № 5. – С. 24–26. [Libman ES, Kaleyeva EV, Ryazanov DP. Kompleksnaya kharakteristika invalidnosti vsledstviye oftal’mopatologii v Rossiyskoy Federatsii. Rossijskaa oftal’mologia onlajn. 2012;(5):24-26. (In Russ.)]
  2. Augood CA, Vingerling JR, de Jong PT, et al. Prevalence of age-related maculopathy in older Europeans: the European Eye Study (EUREYE). Arch Ophthalmol. 2006;124(4):529-535. https://doi.org/10.1001/archopht.124.4.529.
  3. Congdon N, O’Colmain B, Klaver CC, et al. Eye diseases prevalence research group. causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004;122(4):477-485. https://doi.org/10.1001/archopht.122.4.477.
  4. Stahl A. Anti-angiogenic therapy in ophthalmology. In: Book series “Essentials in Ophtalmology”. Vol. 51. Germany: Springer; 2016. 193 р. https://doi.org/10.1007/978-3-319-24097-8.
  5. Бойко Э.В., Сосновский С.В., Березин Р.Д., и др. Антиангиогенная терапия в офтальмологии. – СПб.: ВМедА им. С.М. Кирова, 2013. – С. 292. [Boiko EV, Sosnovskiy SV, Berezin RD, et al. Antiangiogennaya terapiya v oftal’mologii. Saint Petersburg: S.M. Kirov, Military Medical Academy; 2013. P. 292. (In Russ.)]
  6. Das A, Friberg T. Therapy for ocular angiogenesis: principles and practice. Philadelphia: Wolters Kluwer Health / Lippincott Williams & Wilkins; 2011. 375 p. https://doi.org/10.1111/j.1444-0938.2011.00657.x.
  7. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun. 1989;161(2):851-858. https://doi.org/10.1016/0006-291x(89)92678-8.
  8. Stewart MW. The expanding role of vascular endothelial growth factor inhibitors in ophthalmology. Mayo Clin Proc. 2012;87(1): 77-88. https://doi.org/10.1016/j.mayocp.2011.10.001.
  9. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009;116(1):57-65. https://doi.org/10.1016/j.ophtha.2008.10.018.
  10. Busbee BG, Ho AC, Brown DM, et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013;120(5):1046-1056. https://doi.org/10.1016/j.ophtha.2012.10.014.
  11. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-1431. https://doi.org/10.1056/NEJMoa054481.
  12. Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014;121(1):193-201. https://doi.org/10.1016/j.ophtha.2013.08.011.
  13. Бикбов М.М., Файзрахманов Р.Р., Ярмухаметова А.Л. Изменения центральной области сетчатки при влажной форме возрастной макулярной дегенерации после введения ранибизумаба // Вестник офтальмологии. – 2015. – Т. 131. – № 4. – С. 60–65. [Bikbov MM, Fayzrakhmanov RR, Yarmukhametova AL. Central retinal changes after ranibizumab injection for wet age-related macular degeneration. Vestnik oftal’mologii. 2015;131(4):60-65. (In Russ.)]
  14. Boulanger-Scemama E, Sayag D, Ha Chau Tran T, et al. [Ranibizumab and exudative age-related macular degeneration: 5-year multicentric functional and anatomical results in real-life practice. (In French)]. J Fr Ophtalmol. 2016;39(8):668-674. https://doi.org/10.1016/j.jfo.2016.06.001.
  15. Chong V. Ranibizumab for the treatment of wet AMD: a summary of real-world studies. Eye (Lond). 2016;30(11):1526. https://doi.org/10.1038/eye.2016.202.
  16. Owen CG, Fletcher AE, Donoghue M, Rudnicka AR. How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom? Br J Ophthalmol. 2003;87(3): 312-317. https://doi.org/10.1136/bjo.87.3.312.
  17. Degenring RF, Cordes A, Schrage NF. Autologous translocation of the retinal pigment epithelium and choroid in the treatment of neovascular age-related macular degeneration. Acta Ophthalmol. 2011;89(7):654-659. https://doi.org/10.1111/j.1755-3768.2010.01867.x
  18. Van Zeeburg EJ, Maaijwee KJ, Missotten TO, et al. A free retinal pigment epithelium-choroid graft in patients with exudative age-related macular degeneration: results up to 7 years. Am J Ophthalmol. 2012;153(1):120-127. https://doi.org/10. 1016/j.ajo.2011.06.007.
  19. Veckeneer M, Augustinus C, Feron E, et al. OCT angiography documented reperfusion of translocated autologous full thickness RPE-choroid graft for complicated neovascular age-related macular degeneration. Eye (Lond). 2017;31(9):1274-1283. https://doi.org/10.1038/eye.2017.137.
  20. Stopa M, Kocięcki J, Rakowicz P, Dmitriew A. A pedicled autologous choroid RPE patch: a technique to preserve perfusion. Wideochir Inne Tech Maloinwazyjne. 2012;7(3):220-223. https://doi.org/10.5114/wiitm.2011.28910.
  21. Parolini B, di Salvatore AS, Pinackatt SJ. Long-term results of autologous retinal pigment epithelium and choroid transplantation for the treatment of exudative and atrophic maculopathies. Retina. 2020;40(3):507-520. https://doi.org/10.1097/IAE.0000000000002429.
  22. Савостьянова Н.В., Столяренко Г.Е., Скворцова Н.А., Левковец В.Е. Выбор хирургической тактики ведения пациентов с субмакулярными кровоизлияниями большого размера при неоваскулярной форме возрастной макулярной дегенерации (предварительное сообщение) // Современные технологии в офтальмологии. – 2017. – № 1. – С. 251–255. [Savost’yanova NV, Stolyarenko GE, Skvortsova NA, Levkovets VE. Vybor khirurgicheskoy taktiki vedeniya patsiyentov s submakulyarnymi krovoizliyaniyami bol’shogo razmera pri neovaskulyarnoy forme vozrastnoy makulyarnoy degeneratsii (predvaritel’noye soobshcheniye). Sovremennye tekhnologii v oftal’mologii. 2017;(1):251-255. (In Russ.)]
  23. Сосновский С.В., Куликов А.Н., Березин Р.Д., и др. Первый опыт транслокации комплекса «пигментный эпителий – сосудистая „на ножке“» в лечении неоваскулярной возрастной макулярной дегенерации // Современные технологии в офтальмологии. – 2018. – № 1. – С. 324–328. [Sosnovskiy SV, Kulikov AN, Berezin RD, et al. Pervy opyt translokatsii kompleksa «pigmentny epiteliy – sosudistaya „na nozhke“» v lechenii neovaskulyarnoy vozrastnoy makulyarnoy degeneratsii. Sovremennye tekhnologii v oftal’mologii. 2018;(1): 324-328. (In Russ.)]
  24. Патент РФ на изобретение № 2306119 С2. Алапатов С.А., Щуко А.Г., Малышев В.В. Способ лечения макулодистрофии. [Patent RU № 2306119 S2. Alapatov SA, Shchuko AG, Malyshev VV. Sposob lecheniya makulodistrofii. (In Russ.)]. Доступно по: https://yandex.ru/patents/doc/RU2306119C2_20070920. Ссылка активна на 12.04.2020.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Sosnovskii S., Boiko E., Oskanov D., 2021

Creative Commons License
此作品已接受知识共享署名 4.0国际许可协议的许可
 


##common.cookie##